Drug intelligence / Profile preview

GPR171 agonist (ConfometRx)

Development stage: Preclinical
Lead developer: ConfometRx
Modality: Small Molecules
Administration: Intraperitoneal, Intrathecal, Intraplantar

Overview

ConfometRx is developing small molecule agonists of the G protein-coupled receptor 171 (GPR171) for the treatment of chronic and acute pain. GPR171 is a Gi/o-coupled receptor expressed in nociceptive neurons that, when activated by its endogenous ligand BigLEN or synthetic agonists, modulates ion channels to inhibit pain transmission. The program is currently in the preclinical stage, focusing on structure elucidation and lead generation to identify potent and selective candidates. This therapeutic approach aims to provide a novel, non-opioid mechanism for managing inflammatory and neuropathic pain conditions.

Other names: GPR171 programGPR-171 programGPR 171 program

Targets

GPR171 (G protein-coupled receptor 171)

Beyond the preview

Go deeper on GPR171 agonist (ConfometRx).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPR171 agonist (ConfometRx).

Explore the full profile